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AbstrAct
To improve treatment efficacy, we decided to simultaneously target HER1 and 
HER2 with trastuzumab and cetuximab. Following promising preclinical results, 
we conducted a phase 1-2 trial in advanced pancreatic cancer patients after first-
line gemcitabine-based chemotherapy failure. In this single-arm, non-randomized, 
multicenter trial, patients received weekly cetuximab (400mg/m², then 250mg/m²). 
 They were sequentially included in two trastuzumab dose levels: 3.0 or 4.0mg/kg, 
 then 1.5 or 2.0mg/kg/weekly. Endpoints were the objective response rate, 
safety, progression-free (PFS) and overall survival (OS). During phase 1 (n=10 
patients), toxicities were evenly distributed except for skin toxicities that frequently 
caused compliance issues. The higher dose level was defined as the trastuzumab 
recommended dose. During phase 2 (n=39 patients), toxicities were mainly cutaneous 
reactions and asthenia. No objective response was observed. Nine patients were 
stabilized but arrested treatment due to toxicity. Median PFS was 1.8 months (95%CI: 
1.7-2.0 months) and median OS was 4.6 months (95%CI: 2.7–6.6 months). Both were 
positively correlated with skin toxicity severity (P=0.027 and P=0.001, respectively). 
Conventional phase 1 dose-escalation schedules are unsuitable for targeted therapies 
because most cutaneous toxicities are not considered dose-limiting toxicities. The 
compliance issues caused by skin toxicities were particularly detrimental because of 
the toxicity-response correlation.
Oncotarget12797www.impactjournals.com/oncotarget
IntroductIon
Pancreatic cancer is the tenth most common cause 
of cancer in the United States and the fourth leading 
cause of cancer death, with an estimated 42 000 new 
cases and 35 000 associated deaths in 2009 [1]. Despite 
its modest clinical benefit, gemcitabine has been the only 
approved first-line treatment for advanced pancreatic 
cancer for 15 years [2]. Combinations of fluorouracil, 
irinotecan, oxaliplatin and leucovorin (FOLFIRINOX), or 
gemcitabine and nab-paclitaxel are often administered as 
first-line treatment to patients with metastatic pancreatic 
cancer and a good performance status [3,4]. To increase 
the chemotherapy efficacy, several studies have assessed 
the combination of gemcitabine with targeted therapies; 
however, most regimens evaluated in phase 3 clinical trials 
failed to show any overall survival (OS) improvement [5–
9]. Indeed, only one randomized trial [8] (n=569 patients) 
that compared gemcitabine alone or combined with 
erlotinib showed a modest, but significant OS increase 
in the erlotinib+ gemcitabine arm (5.9 vs 6.2 months, 
P=0.025). 
The expression and role of epidermal growth factor 
receptors (EGFR/HER1 and HER2) have been widely 
studied, including in pancreatic cancer [10–15]. Moreover, 
17% to 33% of pancreatic adenocarcinomas overexpress 
HER2, and HER2-positive status has also been correlated 
with shorter survival [10]. With the aim of optimizing 
therapeutic strategies, EGFR expression in pancreatic 
tumors has been determined in some clinical trials in order 
to assess its potential role in predicting treatment efficacy.
As part of a pilot study, the combination of 
trastuzumab (TRA; anti-HER2 monoclonal antibody) 
and gemcitabine was well tolerated, but showed 
limited therapeutic benefit in 34 patients with HER2-
overexpressing metastatic pancreatic cancer [16]. 
Cetuximab (CET; anti-HER1 monoclonal antibody) was 
also assessed in combination with gemcitabine in a phase 2 
 study that included 41 patients with advanced pancreatic 
cancer overexpressing HER1 [17]. However, the results 
of two recent randomized studies combining gemcitabine-
based chemotherapy with CET were disappointing [9,18].
We therefore decided to assess a strategy in which 
HER1 and HER2 are simultaneously targeted. In a 
first preclinical study, we found that the trastuzumab + 
 matuzumab (anti-HER1 antibody) combination was 
more efficient in inhibiting tumor progression in 
mice xenografted with human pancreatic carcinoma 
cell lines than each antibody alone. This synergistic 
effect was associated with a decrease in HER1/HER2 
phosphorylation [19]. We then observed that the TRA + 
 CET combination was more efficient as first- and 
second-line treatment than the standard chemotherapy 
(gemcitabine) in nude mice bearing human pancreatic 
cancer xenografts [20]. Finally, we demonstrated that the 
TRA + CET combination had a better synergistic effect 
than TRA + erlotinib or lapatinib alone in xenografted 
mice [21]. 
Here, we report the results of the first multicenter 
phase 1-2 clinical trial to evaluate the TRA + CET 
combination for the treatment of patients with advanced 
pancreatic cancer after failure of gemcitabine-based first-
line chemotherapy.
results
Over a 15-month period, 10 patients 
were enrolled in the phase 1 and 39 patients 
in the phase 2 of this study (Fig. 1). 
 One patient could not be evaluated in phase 2 because 
of screening failure. Table 2 summarizes the baseline 
characteristics of the enrolled patients. All patients had 
previously received gemcitabine-based chemotherapy and 
many patients had also been treated with a second-line or 
even later cycles of palliative chemotherapy; 60% (phase 1) 
 and 79% (phase 2) of patients had liver metastases and 
half of our study population had serum Ca 19.9 ≥ 65 UI/mL 
 (without jaundice). Safety could not be evaluated in two 
patients (Fig. 1). 
In the phase 1 part, patients in cohort 1 (n=3) 
received two cycles of treatment and patients in cohort 
2 (n=7) received one or two cycles of treatment (but 
for one patient who received six cycles) (Fig. 1). The 
median duration of treatment was 1.9 months (range: 
0.9 -5.8 months). In cohort 1 (n=3), the median relative 
dose intensity (RDI) was 89% for both CET and TRA. 
In cohort 2 (n=7), the median RDI was 65% for CET 
and 67% for TRA. Indeed, toxicities (not considered as 
DLTs) occurred in all patients and were responsible for 
treatment delay or interruption. Premature discontinuation 
was due to disease progression in nine patients and to skin 
toxicity in one patient from cohort 2. This toxicity event 
required a treatment delay longer than 15 days and was 
thus considered as a DLT (the only one in the phase 1 of 
this study). Two patients died from disease-related events. 
The main toxicities included asthenia (grade 1: one event; 
grade 2: four; grade 4: two), anorexia (grade 1: one event; 
grade 2: two; grade 3: one) and rash/acne (grade 1: two 
events; grade 3: five). Grade 3 toxicities were evenly 
distributed, except for skin toxicities that were more 
frequent (two patients in cohort 1, and three patients in 
cohort 2). Based on these results, the recommended doses 
for the phase 2 study were 400 mg/m² CET (loading dose) 
followed by a 250 mg/m² dose, combined with 4.0 mg/m² 
TRA (loading dose) and then 2.0 mg/kg.
In the phase 2 study, 10 patients (26%) received 
one cycle, 21 (55%) received two cycles and 7 patients 
(19%) received three to five cycles of treatment. The 
median treatment duration was 1.8 months (range: 
0.9-4.8 months). The median RDI was 67% for CET 
and 74% for TRA (range: 0% - 100% for both). A RDI 
≥ 80% was obtained in 12 patients (32%) for CET and 
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in 13 patients (34%) for TRA. Eighteen patients (47%) 
prematurely stopped the treatment mainly due to toxicity 
or disease progression (two patients died from disease-
related events). Phase 2 toxicities are detailed in Table 3. 
No toxicity-related death was reported and most adverse 
events were grade 1 or 2. The most commonly reported 
grade 3 adverse events were cutaneous toxicities (n=19). 
Other non-cutaneous grade 3 toxicities included asthenia 
(n=6), metabolism alterations (n=4), hematological (n=4) 
and cardiovascular (n=4) events. The three reported grade 
4 toxicities were thrombosis/embolism (n=2) and asthenia 
(n=1, attributed to the disease). 
Efficacy could be evaluated only in 33 patients 
(Fig. 1) because six patients prematurely withdrew 
from the study (not because of disease progression). 
The phase 2 median follow-up was 3.8 months (range: 
0.4-22.9 months). No objective response was observed. 
The responses relative to the severity of the cutaneous 
toxicities are presented in Table 4A. Nine patients were 
stabilized, but discontinued the treatment due to toxicity.
For the survival analysis, the data of all evaluable 
patients included in the phase 2 study (n=38) were pooled 
table 1: tHerAPY clinical trial: eligibility criteria
Inclusion criteria
previous failure of gemcitabine-based chemotherapy (in adjuvant or metastatic settings)
measurable lesion according to RECIST version 1.0 
WHO performance status ≤ 1
age ≥ 18 years
life expectancy ≥ 3 months 
left ventricular ejection fraction ≥ 55% 
adequate organ function: 
 absolute neutrophil count ≥ 1500 cells per µL 
 hemoglobin > 9 g/dL 
 platelet count ≥ 100 000 cells per µL 
 creatinine function < 1.5 x ULN 
 serum bilirubin ≤ 2.5 x ULN 
 serum transaminases ≤ 5 x ULN)
exclusion criteria
brain metastases or symptomatic leptomeningeal carcinomatosis 
other concurrent cancer (except for skin basal cell carcinoma)
prior chemotherapy with CET or TRA
hypersensitivity to CET or TRA
pregnancy or lactation
fertile patient (man or woman) without effective contraception
concomitant treatment with other experimental drugs or any other anticancer therapy
significant comorbidities such as: 
 cardiovascular disease (documented congestive cardiac failure, high risk   
unstable arrhythmia, angina pectoris requiring treatment, significant   valvulopathy, sign of 
myocardial infarction or unstable high arterial blood pressure), 
 active bleeding, 
 clinically significant active infection, or 
 severe or oxygen-dependent dyspnea at rest
Abbreviations: CET, cetuximab; RECIST, Response Evaluation Criteria in Solid Tumors; TRA, 
trastuzumab; ULN, upper limit of normal
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table 2: demographics and baseline characteristics
Phase 1
n=10
Phase 2
n=38
Age, years
 Median 58.5 63.0
 Range 41-61 43-78
Sex
 Male 5 (50%) 25 (66%)
 Female 5 (50%) 13 (34%)
WHO performance status (PS)
 0 3 (30%) 24 (63%)
 1 6 (60%) 13 (34%)
 2 1* (10%) 1* (3%)
Location of primary tumor
 Head of pancreas 5 (50%) 23 (60%)
 Tail of pancreas 2 (20%) 8 (21%)
 Body of pancreas 3 (30%) 7 (19%)
Primary tumor surgery 4 (40%) 16 (42%)
Primary tumor radiotherapy 2 (20%) 8 (21%)
Previous chemotherapy treatment**
 Adjuvant chemotherapy 2 (20%) 16 (42%)
  with gemcitabine 2 (100%) 15 (94%)
  with fluorouracil 0 - 1 (6%)
 Palliative chemotherapy 10 (100%) 32 (84%)
  with gemcitabine 9 (90%) 20 (62%)
  FOLFIRINOX 1 (10%) 0 -
  1st line 4 (40%) 19 (59%)
  ≥ 2nd line 6 (60%) 13 (41%)
Metastatic disease - Number of sites
 1 9 (90%) 25 (66%)
 2 1 (10%) 9 (24%)
 > 2 4 (10%)
Serum Ca 19.9
 < 65 UI/mL 3 (50%) 14 (52%)
 ≥ 65 UI/mL 3 (50%) 13 (48%)
 Missing 11
Abbreviations: WHO, World Health Organization
* Enrolled patient although not meeting the inclusion criterion of PS ≤ 1
** All patients received gemcitabine (adjuvant or palliative chemotherapy)
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table 3: Phase 2 toxicities (n=38)
Grade 1-2 Grade 3
Cutaneous
 Rash / Acne 18 (47%) 12 (32%)
 Fissures 11 (29%) 3 (8%)
 Pruritus 11 (29%) 2 (5%)
 Skin dryness 20 (53%) 1 (3%)
 Paronychia 9 (24%) 1 (3%)
 Nail toxicity 2 (5%) - -
 Urticaria 1 (3%) - -
Hematological
 Neutropenia 3 (8%) - -
 Lymphopenia 3 (8%) 2 (5%)
 Anemia 20 (52%) 1 (3%)
 Thrombocytopenia 9 (24%) 1 (3%)
Metabolism
 Hyperbilirubinemia - - 3 (8%)
 Hypokalemia 3 (8%) 1 (3%)
Gastrointestinal
 Mucositis  / Stomatitis 17 (44%) 3 (8%)
 Anorexia 18 (47%) 1 (3%)
 Diarrhea 8 (21%) 1 (3%)
 Abdominal Pain 17 (44%) 1 (3%)
 Vomiting 7 (18%) 1 (3%)
Cardiovascular
 Thrombosis / Embolism 1 (3%) 5* (13%)
 Arterial hypertension - - 1 (3%)
Other
 Asthenia 19 (50%) 7** (18%)
 Allergy / Hypersensitivity 1 (3%) 2 (5%)
 Edema 3 (8%) 1 (3%)
* including two grade 4 events; ** including one grade 4 event
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with those of the phase 1 patients who received the same 
TRA dose (cohort 2, n=6). The median follow-up for the 
pooled patients (n=44) was 3.7 months (range: 0.4-22.9 
months). The median PFS was 1.8 months (95% CI: 1.7 - 
2.0 months), while the median OS was 4.6 months (95% CI: 
 2.7 – 6.6 months) (Fig. 2A and 2B). Both PFS and OS 
were significantly (and positively) correlated with the 
severity of skin toxicities (Fig. 2C and 2D), as detailed 
in Table 4B. 
Concerning the ancillary experiments, KRAS status 
could be assessed in 24/44 patients (55%) and HER1 
and HER2 expression levels in 25/44 patients (57%) and 
28/44 patients (64%), respectively (Table 5). Fcγ receptor 
polymorphisms (FcγRIIA-H131R and FcγRIIIA-V158F) 
were determined in 29/44 patients (66%). Four tumors 
(16%) expressed both HER1 and HER2 and in three 
of them a KRAS mutation was detected. No statistical 
correlation was found between these five parameters 
which can be involved in the efficacy of CET [25], 
TRA [26] or mAbs in general [25], and the response to 
Figure 1: Study flow diagram and administration schedules.  1Patients who received at least one dose of treatment. 2Trastuzumab: 
3.0 mg/kg on day 1 and then 1.5 mg/kg on day 8, day 15 and day 22. 3Trastuzumab: 4.0 mg/kg on day 1 and then 2.0 mg/kg on day 8, day 15 
and day 22. 4Patient who completed at least two cycles of treatment or discontinued due to disease progression. 5Patient who received at least 
one dose of treatment and with available data. 6Treatment completion: six cycles of treatment. 7Delay > 15 days. *One patient (cohort 2) 
 received only the first injection after two lines of chemotherapy (gemcitabine in adjuvant setting and gemcitabine-oxaliplatin as first-
line metastatic chemotherapy). The patient died because of acute digestive obstruction (hepatic and peritoneal metastasis) before safety 
evaluation.
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table 4A: response in phase 2 patients relative to the cutaneous toxicity grade
Phase 2 (n=33) stable disease Progressive disease P-value1
All evaluable patients 9 (27%) 24 (73%)
 With grade 0-1 skin toxicities* - 8 (33%)
0.047
 With grade ≥ 2 skin toxicities* 9 (100%) 16 (67%)
 With grade 0-1 skin toxicities** - 10 (42%)
0.020
 With grade ≥ 2 skin toxicities** 9 (100%) 14 (58%)
1correlation between toxicity and response to treatment
*Including all cutaneous toxicities
**Including pruritus, rash/acne, skin dryness, urticaria and paronychia
table 4b: survival in phase 1 + 2 patients relative to the cutaneous toxicity grade
Phase 1 + 2 (n=44) PFsMonths (95% cI)
os
Months (95% cI)
P-value1
PFs os
All evaluable patients 1.8 (1.7-2.0) 4.6 (2.7-6.6)
 with grade 0-1 skin toxicities* 1.1 (0.4-1.9) 2.6 (0.4-4.3)
0.027 0.001
 with grade ≥ 2 skin toxicities* 1.9 (1.8-2.3) 6.0 (3.4-8.3)
 with grade 0-1 skin toxicities** 1.7 (0.6-1.8) 3.3 (0.7-4.6)
0.006 0.002
 with grade ≥ 2 skin toxicities** 1.9 (1.8-3.3) 6.2 (2.7-9.2)
Abbreviations: PFS, progression-free survival; OS, overall survival
1correlation between toxicity and survival, log-rank test 
*Including all cutaneous toxicities
**Including pruritus, rash/acne, skin dryness, urticaria and paronychia
Figure 2: Kaplan Meier progression-free survival and overall survival curves of all patients, and progression-free 
survival and overall survival curves of patients who experienced grade 0-1 or grade ≥ 2 cutaneous toxicities (all types).
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treatment or cutaneous toxicity. 
dIscussIon 
This phase 1-2 trial confirms the feasibility of 
combining cetuximab and trastuzumab for the treatment 
of patients with metastatic pancreatic adenocarcinoma 
after first-line chemotherapy failure. However, the 
primary objective of a 5% to 20% response rate was not 
achieved because no complete or partial response could 
be observed, but only prolonged stable disease in nine 
patients with grade 3-4 cutaneous toxicities. Although the 
results of this trial are negative based on its initial design, 
several lessons can be drawn from our observations. 
First, the absence of complete or partial response 
could lead to question the anticancer activity of combined 
CET-TRA. Indeed, antibodies targeting HER1 or HER2 
are not efficient when administered individually with 
conventional chemotherapy in advanced pancreatic 
cancer [9,16,18]. However, our survival results should 
be compared with those obtained with second-line 
palliative chemotherapy after gemcitabine failure. In our 
study, 23 patients (48%) had already received palliative 
chemotherapy as first-line treatment and 19 patients (40%) 
had already received palliative chemotherapy as second-
line or even later treatment. In a randomized phase 3 trial 
that compared best supportive care (BSC) with combined 
oxaliplatin/folinic acid/5-FU (OFF regimen) as second-
line treatment for patients with advanced pancreatic 
cancer, OS was 4.82 months [95% CI: 4.29–5.35] in the 
OFF arm and 2.30 months [95% CI: 1.76–2.83] in the BSC 
arm (P=0.008) [27]. In another phase 3 randomized trial 
evaluating cisplatin/folinic acid/5-FU vs gemcitabine as 
first- and second-line treatment for patients with metastatic 
pancreatic cancer [28], PFS (from second-line start to 
progression) was 1.6 months, which is similar to our 
results. Moreover, patients in which disease was stabilized 
discontinued the treatment due to toxicity, suggesting that 
more work should be done to determine the optimal dose 
to allow good efficacy with acceptable toxicities.
Indeed, the way the recommended dose was 
determined in the phase 1 trial should be discussed. The 
traditional DLT definition, which focuses on grade 3-4 
toxicities occurring only during the first treatment cycle, 
was designed for conventional chemotherapy. Therefore, 
it may not be appropriate for non-cytotoxic agents for 
which late, different or lower grade toxicities also deserve 
attention [29]. As recently highlighted by Paoletti et al. 
[30], DLT assessment should take into account also lower 
grade toxicities that lead to significant RDI decrease and 
that may also occur after the first treatment cycle. The 
design of phase 1 trials to assess non-cytotoxic agents 
should allow for precise dose adjustments to achieve > 
75% RDI. In our study, the 3+3 standard escalation scheme 
was clearly inappropriate because many grade 3 cutaneous 
toxicities occurred during the phase 1 part (> 50% of 
patients). These events led to a significant RDI decrease 
for both targeted therapies, but could not be considered 
as DLTs. These compliance issues were confirmed by the 
phase 2 study. Specifically, nine patients discontinued 
the treatment due to cutaneous toxicity, although disease 
was stabilized. Moreover, such cutaneous adverse events 
might be more frequent and severe in patients who are 
concomitantly treated with two targeted therapies to block 
both HER1 and HER2 [31,32]. Therefore, extra care 
should be taken when moving from preclinical to clinical 
settings, for example by starting with lower doses than 
those used when these compounds are used individually. 
Finally, the correlation between response or survival 
and severity of cutaneous adverse events, as observed in 
our study, has already been reported. For instance, the 
erlotinib-gemcitabine combination, which showed some 
table 5: KrAs mutational status, Her1/
EGFR and HER2 expression and Fc γ 
receptor polymorphisms (n=44 tumors)
n (%)
 KRAS
 Wild type 9 (38%)
 Mutated 15 (62%)
 Missing 20
HER1
 Negative 10 (40%)
 Positive 15 (60%)
 Missing 19
HER2
 Negative 20 (71%)
 Positive 8 (29%)
 Missing 16
FcγRIIA-H131R
 H/H 8 (28%)
 H/R 19 (65%)
 R/R 2 (7%)
 Missing 15
FcγRIIIA-V158F
 F/F 13 (45%)
 V/F 14 (48%)
 V/V 2 (7%)
 Missing 15
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efficacy improvement compared to the individual drugs 
in patients with pancreatic cancer, was associated with 
increased toxicity [8]. In a retrospective study, 168 patients 
with pancreatic cancer and treated with combined erlotinib 
and gemcitabine were classified in two groups (high and 
low severity), based on the rash intensity [33]. The high 
severity group had longer median OS and PFS than the 
low severity group (both P<0.05); patients suffering from 
particularly severe rash also had a lower risk of death 
(hazard ratio [HR] 0.67, P<0.05). Likewise, in a phase 2 
 trial that enrolled patients with metastatic pancreatic 
cancer (n=64) treated with chemotherapy + CET, the 
presence of a rash was significantly correlated with OS 
[34]. Moreover, as this efficacy-toxicity association had 
been described also in patients with colorectal cancer 
(CRC), Van Cutsem et al. (34) conducted the EVEREST 
trial in 157 patients who experienced grade ≤ 1 skin 
reactions following standard-dose CET. These patients 
were randomly assigned to receive weekly standard-
dose or dose-escalated CET (500 mg/m²) [35]. This dose 
escalation was associated with increased skin toxicity, 
but also with improved response rate and disease control 
rate. A second trial conducted by the same group is in 
progress to determine whether administering escalating 
doses of cetuximab in patients with no early skin toxicity 
could delay the progression of the disease in a significant 
proportion of patients and to study the molecular 
signatures of response (NCT01251536). Similarly, in a 
phase 2 randomized trial in patients with metastatic CRC 
treated with CET, occurrence of grade 2-3 skin toxicities 
(compared with grade 0-1) was correlated with improved 
outcome, including better overall response rate, PFS and 
OS [36]. The authors also highlighted the independence of 
this effect from the KRAS mutation status and suggested 
that patients’ constitutional factors were possibly involved 
in the relationship between response to CET and skin 
toxicity. Concerning the underlying mechanism, as EGFR 
is involved in the maintenance of epithelial homeostasis, 
EGFR inhibitors will target also normal epithelial cells. 
Takata et al. [37] suggested that they might particularly 
affect cell differentiation of epidermal keratinocytes 
and sebaceous glands. Moreover, EGFR and HER2 
dimerization status could explain the different type of 
toxicity induced by EGFR-targeted vs HER2-targeted 
therapies [38]. Finally, another study assessed the safety 
and efficacy of everolimus, an inhibitor of mTOR, which 
is downstream of HER1 and HER2 [39]. However, 
because of toxicity (mainly cutaneous), the recommended 
dose could not be determined in this phase 1-2 trial. In 
view of all these data, future clinical investigations need to 
include both cutaneous and tumor biopsies as they might 
help understanding whether and how the mechanism of 
action and efficacy of EGFR targeted therapies is linked 
to dose-limiting cutaneous reactions. 
In conclusion, although this phase 1-2 trial did 
not bring the expected efficacy results for the treatment 
of advanced pancreatic cancer, one can learn from our 
observations. Conventional phase 1 dose-escalation 
schedules are clearly not appropriate for targeted therapy 
evaluation as most of the induced cutaneous toxicities are 
not considered as DLTs. However, they often entail dose 
reduction or treatment interruption, which is particularly 
detrimental because such toxicities have been positively 
correlated with response to treatment. 
statement of translational relevance
As HER family members are involved in pancreatic 
carcinoma and are activated through dimerization, we 
tested the combination of cetuximab (anti-EGFR/HER1) 
and trastuzumab (anti-HER2 antibody). Following 
promising preclinical results, the aim of this phase 1-2 
trial was to determine the trastuzumab recommended 
dose and to assess the combination safety and efficacy. 
Nine patients out of 39 were stabilized, but stopped the 
treatment because of toxicity. The frequency and severity 
of cutaneous toxicities were correlated with survival, 
but also caused treatment compliance issues. Our study 
demonstrates that the conventional phase 1 design and 
the associated definition of dose-limiting toxicities are 
inappropriate for the evaluation of targeted therapy-based 
regimens, especially when directed against HER1/2. 
Cutaneous toxicities, which are not considered as dose-
limiting, should be taken into account for future dose-
escalation studies to evaluate the potential of anti-HER 
antibody combinations. Investigation of the underlying 
mechanisms might help understanding this significant 
toxicity-efficacy correlation. 
PAtIents And MetHods
study design and patients
We designed a phase 1-2, open-label, single-
arm, non-randomized, multicenter trial. The study 
protocol was approved by our local ethics committee, 
the French competent authorities, and our Institutional 
Gastrointestinal Review Board. The study was conducted 
in accordance with the Declaration of Helsinki and Good 
Clinical Practice. Written informed consent has been 
obtained from all patients before entering the study. The 
phase 1 study was only performed in Montpellier, while 
seven French centers participated in the phase 2 trial. 
Patients with histologically documented, unresectable 
pancreatic adenocarcinoma were enrolled (Fig. 1). The 
other eligibility criteria are listed in Table 1. 
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Phase 1 trial 
The phase 1 trial included two consecutive cohorts 
corresponding to the two TRA dose levels (Fig. 1). Both 
cohorts received weekly intravenous CET at a loading dose 
of 400 mg/m² (day 1, week 1, 90-minute infusion) and then 
at 250 mg/m² (30-minute infusion). Dose escalation was 
provided for TRA only, which was administered 1 hour 
after the end of the CET infusion. A standard 3+3 dose 
escalation design with three to six patients per dose level 
was used. Patients in the first cohort received 3.0 mg/kg 
 TRA as loading dose (day 1, week 1, 90-minute infusion) 
followed by 1.5 mg/kg TRA the following weeks 
(30-minute infusion). If the tolerance was acceptable in 
this first cohort, the second cohort (second dose level) 
received 4.0 mg/kg TRA (loading dose) the first week and 
then 2.0 mg/kg TRA. A treatment cycle was defined as 
four weeks of treatment. The phase 1 primary endpoint 
was the recommended dose of TRA defined as the dose 
for which one type of dose-limiting toxicity (DLT) 
occurred at most in 33% of patients during the first two 
treatment cycles. Adverse events were graded according 
to the National Cancer Institute Common Terminology 
Criteria for Adverse Events (CTCAE), version 3.0. DLT 
was defined as any grade 4 toxicity (except for alopecia, 
or vomiting in the absence of adequate prophylaxis), 
fever or sepsis concurrent with grade 3-4 neutropenia, 
symptomatic thrombocytopenia (hemorrhage), any grade 3 
cardiotoxicity and any toxicity requiring a treatment delay 
longer than 15 days. Treatment was to be administered for 
six complete cycles or until disease progression, patient 
refusal or unacceptable toxicity. 
Phase 2 trial
After completion of the phase 1 part, the phase 2 
trial assessed the CET and TRA combination according 
to the recommended dose defined based on the phase 1 
results. Adverse events were managed as in phase 1. The 
phase 2 primary endpoint was the objective response rate 
(ORR). Every four weeks, target lesions were assessed by 
independent review of thorax-abdomen-pelvis computed 
tomography scans according to Response Evaluation 
Criteria in Solid Tumors (RECIST), version 1.0 [22]. The 
tumor response had to be confirmed by two consecutive 
assessments separated by a four-week interval. Secondary 
endpoints were the tolerance profile, progression-free 
survival (PFS) and OS. Routine laboratory tests were done 
weekly during the first two cycles and every two weeks 
afterwards; physical examination was performed before 
each treatment.
Ancillary study
An optional ancillary study assessed the predictive 
value of individual biomarkers, such as KRAS mutations, 
HER1 and HER2 expression, and Fcγ receptor 
polymorphisms (FcγRIIA-H131R and FcγRIIIA-V158F). 
Expression of HER1 and HER2 in surgical specimens 
was evaluated by immunohistochemistry, as previously 
described [23]. KRAS mutations in tumor tissues 
were determined by high resolution melt analysis and 
direct sequencing [24]. Polymorphism genotyping was 
performed, as previously described [25]. 
statistical methods
Three to 12 patients (3 to 6 per cohort) were planned 
for the phase 1 study. For the phase 2 study, 24 to 55 
patients were required assuming a Simon’s optimal two-
stage design with α=5% and β=10%. The minimal ORR 
value was estimated at 5% and treatment was considered 
promising if ORR ≥ 20%. 
PFS was calculated from inclusion until disease 
progression or death. Patients alive without progression 
were censored at the time of the last contact. OS was 
calculated from inclusion until death. Patients alive or lost 
to follow-up were censored at the time of the last contact. 
The Kaplan-Meier method was used to estimate PFS 
and OS. A p-value of 0.05 was considered as statistically 
significant. 
This study was registered at ClinicalTrials.gov, 
number NCT00923299. 
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